医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Takeda Reports Results for Fiscal Year 2015 (April 2015 – March 2016) and Forecast for Fiscal Year 2016

2016年05月10日 PM03:00
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Takeda Pharmaceutical Company Limited (TOKYO:4502):

 
FY2015: A year of turnaround to sustained growth; achieved full year management guidance
 

 

Underlying revenue up +3.4% (reported revenue growing +1.7% to 1,807.4 billion yen), led by strong performances in Takeda’s growth drivers (GI, Oncology, CNS and Emerging Markets)

Underlying Core Earnings up +8.1% (reported operating profit recorded 130.8 billion yen), aided by cost discipline

Underlying Core EPS up +21.7% (reported EPS was 102 yen), growing 2.5x faster than underlying core earnings

 
Growth Drivers continued to be robust

Consolidated underlying revenue growth of Gastroenterology (GI), Oncology, Central Nervous System (CNS) and Emerging Markets – Takeda’s Growth Drivers – was +9.5% year-to-year

Underlying revenue of GI +23.6%, Oncology +1.0%* and CNS +37.3% year-to-year

Emerging Markets underlying revenue +4.8% year-to-year with continued growth in the key markets of China, Russia and Brazil

*Underlying growth of Oncology excluding VELCADE royalties was +4.4%

 

Broad portfolio of growing products offsets loss of exclusivity decline

ENTYVIO(®) is on track to exceed $2 billion MAT* sales within FY2018

Encouraging uptake of NINLARO(®) and TAKECAB(®)

BRINTELLIX(®) and ADCETRIS(®) showed continued growth

AZILVA(®) and LOTRIGA(®) are contributing to the Japan business

*Moving Annual Total @ constant currency

 
Efficiency gains continue

Project Summit well exceeded full-year target resulting in 30 billion yen additional cost savings

Strong cash flow performance with Operating Free Cash Flow, excluding Actos settlement payment, reaching 230 billion JPY

 
FY2016 management guidance: A year of strategic focus to sustain growth

Underlying Revenue: Mid-single digit growth (%)

Underlying Core Earnings: Low- to mid-teen growth (%)

 

 

Underlying Core EPS: Low- to mid-teen growth (%)

 

Christophe Weber, President and Chief Executive Officer of Takeda, commented:
“FY2015 was a turnaround year. We achieved our management guidance for the second consecutive year, led by our growth drivers, and aided by the global launches of new products such as ENTYVIO and NINLARO. Takeda will continue to deliver innovative new medicines to patients, especially in our focused R&D therapeutic areas. Takeda aims to relentlessly execute our strategic roadmap to deliver our long-term aspiration, and will serve the needs of the patients, with the best in class agility and innovation.”

 

Key figures for the full

year of FY2015 (April 2015 –March 2016)

  FY 2014   FY 2015   Growth
(billion yen)     Underlying2
Revenue 1,777.8 1,807.4 +1.7% +3.4%
Operating Profit -129.3 130.8
Core Earnings1 288.3 292.4 +1.4% +8.1%
Net Profit3 -145.8 80.2
EPS -185 yen 102 yen
Core EPS   225 yen   258 yen   +14.8%   +21.7%

1

  Core Earnings is calculated from operating profit by excluding the impact of exceptional items, such as purchase accounting, amortization and impairment loss of intangible assets, restructuring costs and major litigation costs.

2

Underlying performance aims at understanding the real performance of the business. Underlying Revenue, Underlying Core Earnings, and Underlying Core EPS exclude the same as above and adjusted for acquisitions/divestments and foreign exchange.

3

Attributable to the owners of the company
 

Underlying revenue growth was mainly driven by Takeda’s Growth Drivers: Gastroenterology(GI), Oncology, and Central Nervous System (CNS) in addition to Emerging Markets. The Growth Drivers account for 52% of Takeda’s revenue. GI revenue grew by +23.6% year-to-year, driven by ENTYVIO®. Oncology revenue increased by +1.0%, contributed by VELCADE®, ADCETRIS® and NINLARO®, which has shown an encouraging start in the U.S. since it was launched in December,. Oncology revenue excluding VELCADE royalties grew +4.4%. CNS revenue, including BRINTELLIX®, increased by +37.3%. Emerging Markets revenue grew by +4.8% year-to-year, led by Value Brands (branded generics and Over-The-Counter medicines), with steady growth in China (+11.1%), Russia (+6.2%) and Brazil (+5.7%). However, our future aspiration for growth in Emerging Markets remains strong, in high single digits. Performance in the U.S. (+12.4% year-to-year underlying revenue growth) also contributed to total revenue growth. In Japan, which remains under increasing generic pressure, underlying revenue declined -3.3% year-to-year, but AZILVA® and LOTRIGA® showed significant sales growth of +30.1% and +69.0%, respectively, year-to-year. In addition to these growing products, TAKECAB® and ZAFATEK® are expected to be key sales drivers in Japan after the lifting of the 2-week limit on the prescription period.

Consolidated operating profit was 130.8 billion yen, an increase of 260.1 billion yen compared to the previous year, which exceeded the raised forecast of 120 billion yen announced in February at the FY2015 3rd quarter earnings announcement. Selling, general and administrative expenses increased by 38.2 billion yen (+6.2%) compared to the previous year, mainly due to the increase in sales expenses related to new products in the U.S., but R&D expenses decreased by 36.2 billion yen (-9.5%). Amortization and impairment losses on intangible assets associated with products decreased by 51.3 billion yen (-29.1%), mainly due to 30.5 billion yen of COLCRYS® impairment loss being recognized in 2014 compared to an 8.6 billion yen impairment reversal in fiscal 2015. Other operating income decreased by 82.1 billion yen (-76.6%), mainly due to 53.8 billion yen of revaluation of COLCRYS® contingent consideration liability and 32.8 billion yen of the gains on sales of real estate being recognized in the previous year. Other operating expenses decreased by 277.8 billion yen (-86.2%), mainly due to 274.1 billion yen of loss on Actos litigation in the U.S. being recognized in the previous year.

Project Summit – a company-wide strategic initiative to increase efficiency – continued to produce results, with 30 billion yen of additional savings in FY2015, exceeding the full year target as a result of higher Procurement savings.

As part of its ongoing effort to improve R&D productivity, Takeda is focusing on its core therapeutic areas of Oncology, GI and CNS. Takeda will further strengthen its initiatives and commitment to lead innovation in medicines and provide innovative new drugs to patients around the world including in emerging markets.

FY2015 was positioned for Takeda as a year of turnaround to sustained growth, and Takeda sets the following management guidance for FY2016 as a year of strategic focus to sustain growth.

 

Management Guidance for FY2016

     
  Underlying Growth (%)  
Underlying Revenue Mid-single digit
Underlying Core Earnings Low- to mid-teen
Underlying Core EPS Low- to mid-teen
Dividend per Share   180 yen  
 

Reported Forecast for FY2016

(change vs. FY2015 results)

billion yen FY 2016 1   Change
Revenue 1,720.0 -4.8%
R&D expenses 325.0 -6.0%
Operating Profit 135.0 +3.2%
Net Profit 2 88.0 +9.8%
EPS   112 yen   +9.8%
1   The exchange rate assumptions for FY2016 are 1US$=110 yen and 1 euro=125 yen
2 Attributable to the owners of the company
 

For more details on Takeda’s FY2015 full year results and other financial information, please visit http://www.takeda.com/investor-information/results/

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TOKYO:4502) is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology, central nervous system and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160509006801/en/

CONTACT

Takeda Pharmaceutical Company Limited
Investor Relations
Noriko
Higuchi, +81-(0)3-3278-2306
noriko.higuchi@takeda.com
or
Media
Relations

Japanese media
Tsuyoshi Tada, +81
(0)3-3278-2417
tsuyoshi.tada@takeda.com
or
Media
outside Japan

Jocelyn Gerst, +1-224-554-5542
jocelyn.gerst@takeda.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Optibrium and Bugworks Sign Agreement for StarDrop License
  • Nike Announces Results of the Active Schools Innovation Award in China to Fuel the Culture of Sport and Play for Chinese Youth
  • Samsung Bioepis Announces RENFLEXIS™ (infliximab-abda) Now Available in the United States
  • ニューランド・ラボラトリーズがプロセスエンジニアリング専用ラボを公開
  • 美泰上市全球最先进的人参补剂